ETC 588

Drug Profile

ETC 588

Alternative Names: ESP-24228; ETC-588; Large unilamellar vesicles; LUV

Latest Information Update: 17 May 2007

Price : $50

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Esperion Therapeutics
  • Class Phospholipids
  • Mechanism of Action Apolipoprotein A I stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Acute coronary syndromes; Atherosclerosis

Most Recent Events

  • 16 Feb 2004 Esperion Therapeutics has been acquired by and merged into Pfizer
  • 22 Oct 2003 Espirion has completed enrolment in the ETC 588-004 and ETC 588-005 trials
  • 10 Jun 2003 Esperion is pursuing a corporate agreement to co-promote and co-develop ETC 588 in North America [www.esperion.com]
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top